rs77375493
|
JAK2;INSL6
|
Budd-Chiari Syndrome
|
|
0.770 |
GeneticVariation |
BEFREE |
Here, a 22 year old female with angiographically proven BCS secondary to JAK2/V617F positive Polycythemia vera on therapeutic warfarin presented with acute liver failure (ALF).
|
26626649 |
2016 |
rs77375493
|
JAK2;INSL6
|
Budd-Chiari Syndrome
|
T |
0.770 |
CausalMutation |
CLINVAR |
Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
|
25698270 |
2015 |
rs77375493
|
JAK2;INSL6
|
Budd-Chiari Syndrome
|
|
0.770 |
GeneticVariation |
BEFREE |
The JAK2 V617F mutation was identified in six of 28 patients (21.4%) with idiopathic PVT or BCS and in eight of 45 patients (17.8%) with PVT or BCS secondary to a known prothrombotic factor, but in only one of 38 patients (2.6%) with PVT and cirrhosis (p=0.049).
|
25698270 |
2015 |
rs77375493
|
JAK2;INSL6
|
Budd-Chiari Syndrome
|
T |
0.770 |
CausalMutation |
CLINVAR |
JAK2 V617F mutation and 46/1 haplotype in Chinese Budd-Chiari syndrome patients.
|
23980667 |
2014 |
rs77375493
|
JAK2;INSL6
|
Budd-Chiari Syndrome
|
T |
0.770 |
CausalMutation |
CLINVAR |
Clinical features and etiology of Budd-Chiari syndrome in Chinese patients: a single-center study.
|
23425079 |
2013 |
rs77375493
|
JAK2;INSL6
|
Budd-Chiari Syndrome
|
|
0.770 |
GeneticVariation |
BEFREE |
These results suggest that the JAK2-V617F mutation occurs after the onset of monoclonal haematopoiesis; thus the V617F mutation of JAK2 may not be the primary event in the induction of BCS.
|
19308656 |
2009 |
rs77375493
|
JAK2;INSL6
|
Budd-Chiari Syndrome
|
T |
0.770 |
CausalMutation |
CLINVAR |
The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome.
|
19293426 |
2009 |
rs77375493
|
JAK2;INSL6
|
Budd-Chiari Syndrome
|
|
0.770 |
GeneticVariation |
BEFREE |
Determination of the JAK2 V617F mutation may be useful to recognize patients with Budd-Chiari syndrome with or at risk for the subsequent development of overt myeloproliferative diseases.
|
18600100 |
2008 |
rs77375493
|
JAK2;INSL6
|
Budd-Chiari Syndrome
|
T |
0.770 |
CausalMutation |
CLINVAR |
Determination of the JAK2 V617F mutation may be useful to recognize patients with Budd-Chiari syndrome with or at risk for the subsequent development of overt myeloproliferative diseases.
|
18600100 |
2008 |
rs77375493
|
JAK2;INSL6
|
Budd-Chiari Syndrome
|
|
0.770 |
GeneticVariation |
BEFREE |
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.
|
16762626 |
2006 |
rs77375493
|
JAK2;INSL6
|
Budd-Chiari Syndrome
|
T |
0.770 |
CausalMutation |
CLINVAR |
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.
|
16762626 |
2006 |
rs77375493
|
JAK2;INSL6
|
Budd-Chiari Syndrome
|
|
0.770 |
GeneticVariation |
BEFREE |
JAK2 V617F was identified in 35.6% of 73 patients with EHPVO and in 40% of 20 patients with BCS.
|
17133457 |
2006 |
rs77375493
|
JAK2;INSL6
|
Budd-Chiari Syndrome
|
|
0.770 |
GeneticVariation |
BEFREE |
The purpose of this study was to use JAK2 V617F analysis to re-evaluate the validity of elevated Epo levels as a PV-exclusion criterion in patients with hepatic vein thrombosis [Budd-Chiari syndrome (BCS)].
|
16827884 |
2006 |